The stock has always been very tightly held so any moves tend to be on small volume. I would suspect that some bought in prior to the test announcement expecting better and have moved on... tax loss selling is always a problem at this time of year.
I think the thing to focus on is that none of the top holders are selling.
It's not exactly a friendly market overall at the moment, let alone for a speccy biotech!
If I had spare cash, averaging down wouldn't be a bad strategy!
- Forums
- ASX - By Stock
- FER
- tale of woe
tale of woe, page-5
Featured News
Add FER (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Will Souter, CFO
Will Souter
CFO
Previous Video
Next Video
SPONSORED BY The Market Online